Announcements and Circulars-宜明昂科英文

Investor Relations

Information Disclosure

Announcements and Circulars Analyst Report Financial Reports Listing Documents

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

(1) RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF FINANCIAL OFFICER AND AUTHORIZED REPRESENTATIVE; (2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR; AND (3) APPOINTMENT OF AUTHORIZED REPRESENTATIVE

Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2024

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2023

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2023

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II CLINICAL TRIAL OF IMM2510 FOR THE TREATMENT OF ASPS

VOLUNTARY ANNOUNCEMENT - ORPHAN-DRUG DESIGNATION FROM FDA IN RESPECT OF COMBINATION OF IMM01 AND AZACITIDINE FOR THE TREATMENT OF CMML

VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A PHASE II CLINICAL TRIAL OF IMM2510

VOLUNTARY ANNOUNCEMENT - PRESENTATIONS OF PHASE II RESEARCH STUDIES OF IMM01 AT THE 2023 ASH ANNUAL MEETING

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2023

ARTICLES OF ASSOCIATION

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM47

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2023

Next Day Disclosure Return

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM47

ANNOUNCEMENT INTERIM REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2023

总计 110 1 2 3 456